Hsin‐An Hou

6.3k citations
158 papers · 2.9k · h-index 31

Impact in

  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research
    • Multiple Myeloma Research and Treatments
  • Genetics top 1%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

  • Hematology 106
    • Acute Myeloid Leukemia Research 84
    • Multiple Myeloma Research and Treatments 20
    • Chronic Myeloid Leukemia Treatments 18
  • Molecular Biology 64
    • Epigenetics and DNA Methylation 9
Co-authors
Hwei‐Fang Tien (110 shared papers)Wen‐Chien Chou (96 shared papers)Jih‐Luh Tang (45 shared papers)Ming Yao (42 shared papers)Mei‐Hsuan Tseng (32 shared papers)Woei Tsay (24 shared papers)Shang‐Yi Huang (23 shared papers)Chien‐Yuan Chen (24 shared papers)
Journals
Blood (43 papers)Annals of Hematology (9 papers)Blood Advances (9 papers)Blood Cancer Journal (8 papers)American Journal of Hematology (6 papers)
Partner nations
TaiwanUnited StatesHong Kong

In The Last Decade

Hsin‐An Hou

139 papers receiving 2.9k citations

Peers

Hsin‐An Hou
Comparison fields: 5 of 84
  • Hematology 1.9k
  • Genetics 725
  • Cancer Research 408
  • Molecular Biology 1.3k
  • Immunology 264
Replace Manja Meggendorfer with:
Manja Meggendorfer Germany
Felicitas Thol Germany
Elli Papaemmanuil United States
Martin Wermke Germany
Katharina S. Götze Germany
Valeria Visconte United States
Lukasz P. Gondek United States
Wan‐Jen Hong United States
Guillermo Montalban‐Bravo United States
Stephen E. Langabeer Ireland
Hsin‐An Hou relative to Manja Meggendorfer Germany Manja Meggendorfer's profile →
Citations per field
00.5×1.5×1.8×
Manja Meggendorfer · 1×
Citations per year

Countries citing papers authored by Hsin‐An Hou

Since Specialization
Citations

This map shows the geographic impact of Hsin‐An Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsin‐An Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsin‐An Hou more than expected).

Fields of papers citing papers by Hsin‐An Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsin‐An Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsin‐An Hou. The network helps show where Hsin‐An Hou may publish in the future.

Co-authors

The 25 scholars most cited alongside Hsin‐An Hou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hsin‐An Hou Line = papers co-authored together Hsin‐An Hou links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 158 papers — load more, or switch the sort, to bring in the rest.

#Work
1
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations
Blood ·Jih‐Luh Tang, Hsin‐An Hou, Chien‐Yuan Chen, Chieh‐Yu Liu, Wen‐Chien Chou, Mei‐Hsuan Tseng, Chi‐Fei Huang, Fen‐Yu Lee, Ming-Chih Liu, Ming Yao, Shang‐Yi Huang, Bor‐Sheng Ko, Szu-Chun Hsu, Shang‐Ju Wu, Woei Tsay, Yao‐Chang Chen, Liang‐In Lin, Hwei‐Fang Tien
2009250
2
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations
Blood ·Wen‐Chien Chou, Huai‐Hsuan Huang, Hsin‐An Hou, Chien‐Yuan Chen, Jih‐Luh Tang, Ming Yao, Woei Tsay, Bor‐Sheng Ko, Shang‐Ju Wu, Shang‐Yi Huang, Szu-Chun Hsu, Yao‐Chang Chen, Yen-Ning Huang, Yi-Chang Chang, Fen‐Yu Lee, Min-Chih Liu, Chia‐Wen Liu, Mei‐Hsuan Tseng, Chi‐Fei Huang, Hwei‐Fang Tien
2010166
3
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation
Blood ·Wen‐Chien Chou, Hsin‐An Hou, Chien‐Yuan Chen, Jih‐Luh Tang, Ming Yao, Woei Tsay, Bor-Shen Ko, Shang‐Ju Wu, Shang‐Yi Huang, Szu-Chun Hsu, Yao‐Chang Chen, Yen-Ning Huang, Yi-Chang Chang, Fen‐Yu Lee, Ming‐Chi Liu, Chia‐Wen Liu, Mei‐Hsuan Tseng, Chi‐Fei Huang, Hwei‐Fang Tien
2010157
4
WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system
Blood ·Hsin‐An Hou, Tai‐Chung Huang, Liang‐In Lin, Chieh‐Yu Liu, Chien‐Yuan Chen, Wen‐Chien Chou, Jih‐Luh Tang, Mei‐Hsuan Tseng, Chi‐Fei Huang, Ying‐Chieh Chiang, Fen‐Yu Lee, Ming-Chih Liu, Ming Yao, Shang‐Yi Huang, Bor‐Sheng Ko, Szu-Chun Hsu, Shang‐Ju Wu, Woei Tsay, Yao‐Chang Chen, Hwei‐Fang Tien
2010117
5
Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation
The Journal of Experimental Medicine ·Reina Nagase, Daichi Inoue, Alessandro Pastore, Takeshi Fujino, Hsin‐An Hou, Norimasa Yamasaki, Susumu Goyama, Makoto Saika, Akinori Kanai, Yasuyuki Sera, Sayuri Horikawa, Yasunori Ota, Shuhei Asada, Yasutaka Hayashi, Kimihito C. Kawabata, Reina Takeda, Hwei‐Fang Tien, Hiroaki Honda, Omar Abdel‐Wahab, Toshio Kitamura
2018113
6
The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution
Blood ·Shang‐Ju Wu, Yuan‐Yeh Kuo, Hsin‐An Hou, Li-Yu Li, Mei‐Hsuan Tseng, Chi‐Fei Huang, Fen‐Yu Lee, Ming-Chih Liu, Chia‐Wen Liu, Chien‐Ting Lin, Chien‐Yuan Chen, Wen‐Chien Chou, Ming Yao, Shang‐Yi Huang, Bor‐Sheng Ko, Jih‐Luh Tang, Woei Tsay, Hwei‐Fang Tien
2012111
7
Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome
EBioMedicine ·Bor‐Sheng Ko, Yu‐Fen Wang, Jeng-Lin Li, Chi‐Cheng Li, Pei-Fang Weng, Szu-Chun Hsu, Hsin‐An Hou, Huai‐Hsuan Huang, Ming Yao, Chien‐Ting Lin, Jia‐Hau Liu, Cheng‐Hong Tsai, Tai‐Chung Huang, Shang‐Ju Wu, Shang‐Yi Huang, Wen‐Chien Chou, Hwei‐Fang Tien, Chi-Chun Lee, Jih‐Luh Tang
201873
8
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
Blood Cancer Journal ·Hsin‐An Hou, Cheng‐Hong Tsai, Chien‐Chin Lin, Wen‐Chien Chou, Yuan‐Yeh Kuo, Chieh‐Yu Liu, Mei‐Hsuan Tseng, Yen‐Ling Peng, Ming-Chih Liu, Chia‐Wen Liu, Xiu‐Wen Liao, Liang‐In Lin, Ming Yao, Jih‐Luh Tang, Hwei‐Fang Tien
201867
9
Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival
Blood ·Tiffany Ting‐Fang Shih, Hsin‐An Hou, Chieh‐Yu Liu, Bang‐Bin Chen, Jih‐Luh Tang, Hsuan‐Yu Chen, Shwu‐Yuan Wei, Ming Yao, Shang‐Yi Huang, Wen‐Chien Chou, Szu-Chun Hsu, Woei Tsay, Chih‐Wei Yu, Chao‐Yu Hsu, Hwei‐Fang Tien, Pan‐Chyr Yang
200860
10
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
Annals of Hematology ·Yuwen Wang, Cheng‐Hong Tsai, Chien‐Chin Lin, Feng‐Ming Tien, Yu‐Wen Chen, Hsing-Yu Lin, Ming Yao, Yun‐Chu Lin, Chien‐Ting Lin, Chieh‐Lung Cheng, Jih‐Luh Tang, Wen‐Chien Chou, Hsin‐An Hou, Hwei‐Fang Tien
202055
11
An mRNA expression signature for prognostication inde novoacute myeloid leukemia patients with normal karyotype
Oncotarget ·Ming‐Kai Chuang, Yu‐Chiao Chiu, Wen‐Chien Chou, Hsin‐An Hou, Mei-Hsuan Tseng, Yi-Yi Kuo, Yidong Chen, Eric Y. Chuang, Hwei‐Fang Tien
201551
12
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
American Journal of Hematology ·Shang‐Ju Wu, Jih‐Luh Tang, Chien‐Ting Lin, Yuan‐Yeh Kuo, Li-Yu Li, Mei‐Hsuan Tseng, Chi‐Fei Huang, Yen‐Jun Lai, Fen‐Yu Lee, Ming-Chih Liu, Chia‐Wen Liu, Hsin‐An Hou, Chien‐Yuan Chen, Wen‐Chien Chou, Ming Yao, Shang‐Yi Huang, Bor‐Sheng Ko, Woei Tsay, Hwei‐Fang Tien
201350
13
Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia
Blood ·Chieh‐Lung Cheng, Hsin‐An Hou, Ming-Cheng Lee, Chieh‐Yu Liu, Jie-Yang Jhuang, Yan-Jun Lai, Chung‐Wu Lin, Huan-Yuan Chen, Fu‐Tong Liu, Wen‐Chien Chou, Chien‐Yuan Chen, Jih‐Luh Tang, Ming Yao, Shang‐Yi Huang, Bor‐Sheng Ko, Shang‐Ju Wu, Woei Tsay, Hwei‐Fang Tien
201348
14
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
Annals of Hematology ·Shang‐Yi Huang, Chung‐Wu Lin, Hsiu‐Hsia Lin, Ming Yao, Jih‐Luh Tang, Shang‐Ju Wu, Yao‐Chang Chen, Hsiao‐Yun Lu, Hsin‐An Hou, Chien‐Yuan Chen, Wen‐Chien Chou, Woei Tsay, (unknown), Hwei‐Fang Tien
201448
15
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Haematology ·Amer M. Zeidan, Kiyoshi Ando, Odile Beyne Rauzy, Mehmet Turgut, Ming‐Chung Wang, Roberto Cairoli, Hsin‐An Hou, Yok‐Lam Kwong, Montserrat Arnán, Stef Meers, Vinod Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Julie Niolat, Pedro Marques Ramos, Hans D. Menssen, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker
202347
16
Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia
Leukemia Research ·Hsin‐An Hou, Wen‐Chien Chou, Liang‐In Lin, Jih‐Luh Tang, Mei‐Hsuan Tseng, Chi‐Fei Huang, Ming Yao, Chien‐Yuan Chen, Woei Tsay, Hwei‐Fang Tien
200747
17
Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA
Cancer Research ·Tong‐You Wade Wei, Pei‐Yu Wu, Ting‐Jung Wu, Hsin‐An Hou, Wen‐Chien Chou, Chieh‐Lin Jerry Teng, Chih-Ru Lin, Jo‐Mei Maureen Chen, Ting-Yang Lin, Hsiang‐Chun Su, Chia-Chi Flora Huang, Chang‐Tze Ricky Yu, Shih‐Lan Hsu, Hwei‐Fang Tien, Ming‐Daw Tsai
201646
18
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
Journal of Biomedical Science ·Hsin‐An Hou, Hwei‐Fang Tien
202045
19
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
BMC Cancer ·Huai‐Hsuan Huang, Fei-Yun Chen, Wen‐Chien Chou, Hsin‐An Hou, Bor‐Sheng Ko, Chien‐Ting Lin, Jih‐Luh Tang, Chi‐Cheng Li, Ming Yao, Woei Tsay, Szu-Chun Hsu, Shang‐Ju Wu, Chien‐Yuan Chen, Shang‐Yi Huang, Mei‐Hsuan Tseng, Hwei‐Fang Tien, Ruey‐Hwa Chen
201944
20
Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection
Annals of Hematology ·Weili Ma, Hsin‐An Hou, Ya-Jui Hsu, Yin-Kai Chen, Jih‐Luh Tang, Woei Tsay, Po‐Ting Yeh, Chung‐May Yang, Chang‐Ping Lin, Hwei‐Fang Tien
201643

About Hsin‐An Hou

Hsin‐An Hou is a scholar working on Hematology, Molecular Biology, Genetics, Cancer Research and Immunology, having authored 158 papers that have together received 2.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (84 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (50 papers), Multiple Myeloma Research and Treatments (20 papers), Chronic Myeloid Leukemia Treatments (18 papers), Cancer Genomics and Diagnostics (14 papers), Lymphoma Diagnosis and Treatment (12 papers), Epigenetics and DNA Methylation (9 papers) and Eosinophilic Disorders and Syndromes (9 papers). The work is most often cited by research in Hematology (1.9k citations), Genetics (725 citations), Cancer Research (408 citations), Molecular Biology (1.3k citations) and Immunology (264 citations). Hsin‐An Hou has collaborated with scholars based in Taiwan, United States and Hong Kong. Frequent co-authors include Hwei‐Fang Tien, Wen‐Chien Chou, Jih‐Luh Tang, Ming Yao, Mei‐Hsuan Tseng, Woei Tsay, Shang‐Yi Huang, Chien‐Yuan Chen, Shang‐Ju Wu and Bor‐Sheng Ko. Their work appears in journals such as Blood, Annals of Hematology, Blood Advances, Blood Cancer Journal and American Journal of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manja MeggendorferBreakdown of academic impact, for papers by Felicitas TholBreakdown of academic impact, for papers by Elli PapaemmanuilBreakdown of academic impact, for papers by Martin WermkeBreakdown of academic impact, for papers by Katharina S. GötzeBreakdown of academic impact, for papers by Valeria VisconteBreakdown of academic impact, for papers by Lukasz P. GondekBreakdown of academic impact, for papers by Wan‐Jen HongBreakdown of academic impact, for papers by Guillermo Montalban‐BravoBreakdown of academic impact, for papers by Stephen E. Langabeer